Kymriah cost dispute goes to heart of pharma's pricing row

9 February 2018

A peer-reviewed journal of health policy thought and research has published an article claiming that the US price tag of the pioneering CAR-T therapy Kymriah (tisagenlecleucel) is overpriced by 197%.

Swiss pharma giant Novartis (NOVN: VX) has slipped a price tag of $475,000 on the one-time infusion of Kymriah in the USA, which has so been approved by the US Food and Drug Administration (FDA) for the treatment of pediatric and young adult acute lymphoblastic leukemia (ALL).

In the next few years, Kymriah is expected to receive marketing approval in other countries and for other indications, including adult acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and small lymphocytic lymphoma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK